Effect of RGH-2716 on Learning and Memory Deficits of Young and Aged Rats in Water-Labyrinth

Paróczai, M; Kiss, Béla; Kárpáti, E

doi:10.1016/s0361-9230(97)00429-2

Cited by 11 publications

(6 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Experiments were performed in a three-choice-point water labyrinth (Paróczai et al 1998). The water tank, made from rustproof metal, was 1 m long, 60 cm wide and 60 cm deep.…”

Section: Apparatusmentioning

confidence: 99%

See 1 more Smart Citation

Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats

2004

View full text Add to dashboard Cite

show abstract

“…Experiments were performed in a three-choice-point water labyrinth (Paróczai et al 1998). The water tank, made from rustproof metal, was 1 m long, 60 cm wide and 60 cm deep.…”

Section: Apparatusmentioning

confidence: 99%

“…The influence of the D 3 ligands on spatial memory was investigated in a water labyrinth test reported earlier (Paróczai et al 1998).…”

Section: Introductionmentioning

confidence: 99%

Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats

2004

View full text Add to dashboard Cite

show abstract

“…The water labyrinth test is a classical maze paradigm making use of the motivation of the animals to escape from the water. This method is appropriate for probing the effect of drugs on memory disturbance that was induced by amnestic agents (Paróczai et al, 1998).…”

Section: Introductionmentioning

confidence: 99%

Scopolamine provocation-based pharmacological MRI model for testing procognitive agents

et al. 2015

View full text Add to dashboard Cite

There is a huge unmet need to understand and treat pathological cognitive impairment. The development of disease modifying cognitive enhancers is hindered by the lack of correct pathomechanism and suitable animal models. Most animal models to study cognition and pathology do not fulfil either the predictive validity, face validity or construct validity criteria, and also outcome measures greatly differ from those of human trials. Fortunately, some pharmacological agents such as scopolamine evoke similar effects on cognition and cerebral circulation in rodents and humans and functional MRI enables us to compare cognitive agents directly in different species. In this paper we report the validation of a scopolamine based rodent pharmacological MRI provocation model. The effects of deemed procognitive agents (donepezil, vinpocetine, piracetam, alpha 7 selective cholinergic compounds EVP-6124, PNU-120596) were compared on the blood-oxygen-level dependent responses and also linked to rodent cognitive models. These drugs revealed significant effect on scopolamine induced blood-oxygen-level dependent change except for piracetam. In the water labyrinth test only PNU-120596 did not show a significant effect. This provocational model is suitable for testing procognitive compounds. These functional MR imaging experiments can be paralleled with human studies, which may help reduce the number of false cognitive clinical trials.

show abstract

“…The development of many drugs interacting with ion channels was terminated (in alphabetical order): DMP- 543 [138] and an increase of parietal regional cerebral blood flow in AD patients [139], the clinical results were disappointing [140]), MEM-1003 (BAY-Z-4406, Memory Pharmaceuticals under license from Bayer; a L-type voltage-gated calcium channel [141]), nerispirdine (HP-184, Hoechst, now sanofi; an inhibitor of Mtype K + channels), nicardipine (YC-93, Yamanouchi [142]), nifedipine (BAY-A-1040, Adalat, Bayer [143]), nimodipine (BAY-E-9736, Nimotop, Bayer [144][145][146][147][148][149][150][151][152]), nitrendipine (BAY-E-5009; Bayotensin, Bayer; all L-type voltage-gated calcium channels [153,154]), NP-34 (NP-04634; Noscira, formerly Neuropharma; a dual calcium channel blocker and acetylcholinesterase inhibitor [155]), NS-649 (Neu-roSearch; a neuron-specific calcium channel blocker [156]), NSD-761 (NeuroSearch; a selective ion channel modulator); RGH-2716 (TDN-345; a nootropic neuroselective ion channel blocker; Takeda in collaboration with Gedeon Richter [157][158][159]), SNX-482 (R-type calcium channel blocker of Neurex, now Elan Pharmaceuticals [160][161][162]), SPI-017 (Sucampo; selective type-2 chloride channel activator), tamolarizine (NC-1100, calcium channel blocker, Nippon Chemiphar [163][164][165]), VRX-698 (Valeant Pharmaceuticals International; a potassium channel opener), and XE-991 (Bristol-Myers Squibb; a KCNQ potassium channel blocker [166,167]).…”

Section: Drugs Interacting With Ion Channels (Non-receptors)mentioning

confidence: 99%

Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs

Froestl

Pfeifer

Muhs

2013

JAD

View full text Add to dashboard Cite

Cognitive enhancers (nootropics) are drugs to treat cognition deficits in patients suffering from Alzheimer's disease, schizophrenia, stroke, attention deficit hyperactivity disorder, or aging. Cognition refers to a capacity for information processing, applying knowledge, and changing preferences. It involves memory, attention, executive functions, perception, language, and psychomotor functions. The term nootropics was coined in 1972 when memory enhancing properties of piracetam were observed in clinical trials. In the meantime, hundreds of drugs have been evaluated in clinical trials or in preclinical experiments. To classify the compounds, a concept is proposed assigning drugs to 19 categories according to their mechanism(s) of action, in particular drugs interacting with receptors, enzymes, ion channels, nerve growth factors, re-uptake transporters, antioxidants, metal chelators, and disease modifying drugs, meaning small molecules, vaccines, and monoclonal antibodies interacting with amyloid-β and tau. For drugs, whose mechanism of action is not known, they are either classified according to structure, e.g., peptides, or their origin, e.g., natural products. The review covers the evolution of research in this field over the last 25 years.

show abstract

Effect of RGH-2716 on Learning and Memory Deficits of Young and Aged Rats in Water-Labyrinth

Cited by 11 publications

References 37 publications

Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats

Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats

Scopolamine provocation-based pharmacological MRI model for testing procognitive agents

Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs

Contact Info

Product

Resources

About